Company Overview and News
2018-09-13 reuters - 1
NEW YORK, Sept 13 (Reuters) - U.S. shale producers are locking in prices for their production as much as three years into the future in a sign that strong domestic crude pricing is nearing a peak, according to market sources familiar with money flows.
DNR 7018 CME SM EGN CXO
NEW YORK (Reuters) - U.S. shale producers are locking in prices for their production as much as three years into the future in a sign that strong domestic crude pricing is nearing a peak, according to market sources familiar with money flows.
DNR 7018 CME SM EGN CXO
2018-09-12 zacks - 1
While the lack of takeaway capacity in the prolific Permian play could mar the region’s growth prospects in the near future, Diamondback Energy, Inc. (FANG - Free Report) seems to be rather unfrazzled by this dilemma. The Texas-based Permian pure-play has been strategically working to further boost its presence in the region. While many producers have been reducing their spending levels in Permian and shifting their focus to other shale plays, Diamondback does not intend to re-evaluate its strategies.
JNEEP EGN CG JONE FANG
(Reuters) - Private equity firm Carlyle Group LP said on Tuesday it would fund the development of Diamondback Energy Inc’s oil and gas assets in the prolific Permian basin of Texas.
EGN CG FANG
Stocks were indicated to open lower on Tuesday morning as continued profit-taking in September is a theme. Despite the choppy markets, it’s important to know that the major stock market indexes are still quite close to all-time highs. Investors also need to consider that buying the sell-offs has so far in 2018 been less rewarding than in prior years.
PCG HAL NOV WDC NKE GNRC EGN AEP MYGN MS CBS CBS.A BHGE CBS.WD BHI CZR TRI CPV FANG
2018-09-05 investorplace - 1
The last few weeks have been tricky ones for energy investors. Some oil stocks have struggled, while others have managed to rally. The market has taken each of these names on a case-by-case basis.
APC AMID KML XOM SRCI CTLR MDR EPD EQT KMI EGN CLR KMR CVB KMRFZ AEUA MCDFF FANG
2018-09-04 zacks - 1
For the longest time, Permian Basin has been the golden shale area of the United States. Crude output from the Permian has been on fire with the United States becoming the world’s numero uno oil producing country in 2017. While production in the Permian is soaring, its takeaway capacity in the region is not increasing to that proportion. This mismatch presents a massive opportunity to midstream companies as well as the refining players.
APA NBL XOM CXO PE VLO MPC EOG TSNU ETP DK RSPP CVX HFC EGN PAA OXY TSN FANG
2018-09-03 seekingalpha - 3
This article is part of a series that provides an ongoing analysis of the changes made to Carl Icahn’s 13F portfolio on a quarterly basis. It is based on Icahn’s regulatory 13F Form filed on 08/14/2018. Please visit our Tracking Carl Icahn’s Portfolio series to get an idea of his investment philosophy and our previous update for the fund’s moves during Q1 2018.
VLTCP CQP CVI SDRPQ FCX TPCA VMW ENZN AFNL HRI NWL EGN VLTCW CI WBT VKSC ARII LNG GLPI SD XRX IEP NAV CNDT SDOCQ HLF UAN DVMT ERI CVRR VLTC MTW SDRXP HTZ SDRXQ
2018-09-02 seekingalpha - 4
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson’s 13F stock portfolio on a quarterly basis. It is based on Paulson’s regulatory 13F Form filed on 08/14/2018. Please visit our Tracking John Paulson’s Paulson & Company Portfolio series to get an idea of his investment philosophy and our previous update for the fund’s moves during Q1 2018.
AKRX VST TWX AU ENL SHPG HAWK VIAB AABA DST OSG.WI AEM INSW MITL AGG SYMX AET FOX TMUSP TMUS RGORF BKD GOLD UTX 2840 TWC OGISD NSW OGSRW MDT SES CZR OGSWW OGISZ XLGLF QCOM INSW.WI FOXA OGSBW ENDP NMRK XL CTL RRS GLD AULGF OSG VRX ODP AGN EGN MON HZNP OSGB DISH OVSPW CMCSA CACQ COL GOLD OVSPA OVSPD VSTE THM BHS
Diamondback Energy Inc.’s (FANG - Free Report) premium Permian acreage has been quite a boost to the company’s performance over the past couple of years. Notably, over the past two years, its shares have increased more than 25% against the stocks in the broader industry’s collectively decline of around 18%.
EGN FANG EOG
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to EGN / Energen Corp. on message board site Silicon Investor.
as of ET